DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

Information source: Par Pharmaceutical, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: To Determine Bioequivalence Under Fed Conditions.

Intervention: Buspirone HCl (Drug); Buspirone HCl (Drug); Buspar (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Par Pharmaceutical, Inc.

Official(s) and/or principal investigator(s):
Samuel Surfaty, MD, Principal Investigator, Affiliation: Phoenix International Life Sciences Inc

Summary

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Clinical Details

Official title: Comparative, Randomized, 3-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar)15 mg Buspirone HCl Tablets Following Administration of a 30 mg Dose in Healthy Adult Males Under Fed and Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Rate and extent of absorption

Detailed description: To compare the single-dose bioavailability of Par and Bristol-Myers Squibb (Buspar) 15 mg buspirone HCl tablets, following administration of a 30 mg dose, under fed conditions. In addition, the bioavailability of the Par product was compared under fed and fasting conditions.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy male volunteers, 18-45 years of age

- Weighing at least 60 kg, who are within 10% of their ideal weights (Table of

"Desirable Weights of Adults", metropolitan Life Insurance Company, 1983)

- Physical examination and laboratory tests of hematologic, hepatic and renal

functions.

- Medically healthy subjects with clinically normal laboratory profiles will be

enrolled in the study Exclusion Criteria:

- History or presence of significant cardiovascular, pulmonary, hepatic, renal,

hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.

- In addition, the presence of alcoholism or drug abuse within the past year:

hypersensitivity or idiosyncratic reaction to buspirone HCl.

- Subjects who have been receiving monoamine oxidase inhibitors.

- Subjects who have been on an abnormal diet (for whatever reason) during the 28 days

preceding the study.

- Subjects who, through completion of the study, would have donated in excess of 500 mL

blood in 14 days, or 500-750 mL blood in 14 days (unless approved by the Principal Investigator, 1000 mL blood in 90 days, 1250 mL blood in 120 days, 1500 mL blood in 180 days, 2000 mL blood in 270 days, 2500 mL blood in 1 year.

- Subjects who have participated in another clinical trial with 28 days of study start.

Locations and Contacts

Phoenix International Life Sciences inc, St-Laurent, Quebec H4R 2N6, Canada
Additional Information

Starting date: July 1998
Last updated: April 1, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017